Brief: Tonix Pharmaceuticals Holding Corp - Discontinued Enrollment And Terminated Phase 2 Catalyst Study - SEC Filing
25/04/2025 22:03
April 25 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS HOLDING CORP - DISCONTINUED ENROLLMENT AND TERMINATED PHASE 2 CATALYST STUDY - SEC FILING TONIX PHARMACEUTICALS - EVALUATING NEW STUDY DESIGNS AND NEW ENDPOINTS FOR FURTHER DEVELOPMENT OF TNX-1300 Source text: [ID:n0001999371-25-004807] Further company coverage: TNXP.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview